Multi-Protein Panels for Co-Pathology Detection & Biological Patient Stratification; Towards Personalised Medicine in Neuro Trials. Learnings from HER-096 development for Parkinson’s Disease
- Herantis approach to developing personalised medicine: How can oncology-style biological characterisation help define the right target patient population for disease modifying therapies
- Deep biological characterisation of patients and HER-096 responses across multiple analysis platforms together with digital biomarker readouts
- Including baseline multi‑protein panels to capture copathologies, such as AD pathology
- Potential for novel biomarkers, e.g. skin‑biopsy + seeding assay for less‑invasive stratification tests to boost recruitment
- Learnings for Phase 2 clinical development